DHR
FY2026 Q2 · Calendar Q3 2026
Danaher Corporation
Danaher delivered a Q2 beat with revenue of $6.3 billion (core growth +4.5% YoY) and adjusted EPS of $1.94, ahead of the $1.85 consensus estimate. The company raised full-year adjusted EPS guidance to $8.45–$8.60 from $8.35–$8.55. Despite these positives, shares fell approximately 11% on report day with 6.6x normal volume — the market focused on bioprocessing shipment timing delays that pressured near-term equipment revenue conversion, even though underlying order growth remained in the mid-teens. The Masimo acquisition closed in early June, earlier than expected, and is immediately accretive. New product launches across life sciences (Biacore 8S, SCIEX novus V55) and diagnostics (Access pTau217 Alzheimer's blood assay) broaden the growth base. The stock has since recovered most of the initial decline, trading at $199.08 as of July 28. With a bullish score of 82 and confident…
EPS surprise+4.9%
Market move-11.0%
